The efficacy of parecoxib on systemic inflammatory response associated with cardiopulmonary bypass during cardiac surgery

Aims Cardiopulmonary bypass (CPB) during cardiac surgery is well known to be associated with the development of a systemic inflammatory response. The efficacy of parecoxib in attenuating this systemic inflammatory response is still unknown. Methods Patients undergoing elective mitral valve replacement with CPB were assessed, enrolled and randomly allocated to receive parecoxib (80mg) or placebo. Blood samples were collected in EDTA vials for measuring serum cytokine concentrations, troponin T, creatinekinase myocardial-brain isoenzyme CK-MB concentrations and white cell counts. Results Compared with the control group, IL-6 and IL-8-values in the parecoxib group increased to a lesser extent, peaking at 2h after the end of CPB (IL-6 31.8pgml1 +/- 4.7 vs. 77.0pgml1 +/- 14.1, 95% CI 47.6, 42.8, P < 0.001; IL-8 53.6pgml1 +/- 12.6 vs. 105.7pgml1 +/- 10.8, 95% CI 54.8, 49.4, P < 0.001). Peak concentrations of anti-inflammatory cytokine IL-10 occurred immediately after termination of CPB and were higher in the parecoxib group (115.7pgml1 +/- 10.5 vs. 88.4pgml1 +/- 12.3, 95% CI 24.7, 29.9, P < 0.001). Furthermore, the increase in neutrophil counts caused by CPB during cardiac surgery was inhibited by parecoxib. The increases in serum troponin T and CK-MB concentrations were also significantly attenuated by parecoxib in the early post-operative days. Peak serum concentrations of CK-MB in both groups occurred at 24h post-CPB (17.4gl1 +/- 5.2 vs. 26.9gl1 +/- 6.9, 95% CI 10.9, 8.1, P < 0.001). Peak troponin T concentrations occurred at 6h post-bypass (2gl1 +/- 0.62 vs. 3.5gl1 +/- 0.78, 95% CI 1.7, 1.3, P < 0.001). Conclusion Intra-operative parecoxib attenuated the systemic inflammatory response associated with CPB during cardiac surgery and lowered the biochemical markers of myocardial injury.